CEO: Bahija Jallal, Ph. D., Executive Vice President, Astrazeneca and Head of MedImmune

Founded: 1988 as Molecular Vaccines, Inc.; name changed to MedImmune in 1990

About MedImmune: A leading global biologics R&D powerhouse, MedImmune comprises nearly half of AstraZeneca’s overall R&D portfolio and currently has more than 120 research projects and product candidates. The company’s focus includes three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease.

Why Gaithersburg: The company was born here, and acquired by Astra Zeneca in 2007. Today, Gaithersburg is home to MedImmune’s headquarters with 2500 employees.